Dendritic cell activation and maturation induced by recombinant calreticulin fragment 39-272

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 5, 2015, Pages 7288-7296

  Li, Yue ^a   Zeng, Xiaoli ^a   He, Lijuan ^a   Yuan, Hui ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Calreticulin; DC; PI3K Akt; TLR4 CD14

Indexed keywords

CALRETICULIN; CD14 ANTIGEN; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; LECTIN; PROTEIN P40; TOLL LIKE RECEPTOR 4;

ADAPTIVE IMMUNITY; ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BONE MARROW DERIVED DENDRITIC CELL; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; IMMUNOSTIMULATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ESCHERICHIA COLI; MURINAE;

EID: 84937041347     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. [1] Michalak M, Corbett EF, Mesaeli N, Nakamura K, Opas M. Calreticulin: one protein, one gene, many functions. Biochem J 1999; 2: 281-292.
2. [2] Krause KH, Michalak M. Calreticulin. Cell 1997; 88: 439-443.
3. [3] Burns K, Helgason CD, Bleackley RC, Michalak M. Calreticulin in T-lymphocytes. Identification of calreticulin in T-lymphocytes and demonstration that activation of T cells correlates with increased levels of calreticulin mRNA and protein. J Biol Chem 1992; 267: 19039-19042.
4. [4] Cho JH, Homma KJ, Kanegasaki S, Natori S. Activation of human monocyte cell line U937 via cell surface calreticulin. Cell Stress Chaperones 2001; 6: 148-152.
5. [5] Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123: 321-334.
6. [6] Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Métivier D, Laro-chette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
7. [7] Porcellini S, Traggiai E, Schenk U, Ferrera D, Matteoli M, Lanzavecchia A, Michalak M, Grassi F. Regulation of peripheral T cell activation by calreticulin. J Exp Med 2006; 203: 461-471.
8. [8] Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, Duggan C, Belldegrun AS, Dubinett SM. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 2006; 177: 3582-3589.
9. [9] Hong C, Qiu X, Li Y, Huang Q, Zhong Z, Zhang Y, Liu X, Sun L, Lv P, Gao XM. Functional analysis of recombinant calreticulin fragment 39-272: implications for immunobiological activities of calreticulin in health and disease. J Immunol 2010; 185: 4561-459.
10. [10] Osterloh A, Kalinke U, Weiss S, Fleischer B, Breloer M. Synergistic and differential modulation of immune responses by Hsp60 and lipopolysaccharide. J Biol Chem 2007; 282: 4669-4680.
11. [11] Vassilakos A, Michalak M, Lehrman MA, Williams DB. Oligosaccharide binding characteristics of the molecular chaperones calnexin and calreticulin. Biochemistry 1998; 37: 3480-3490.
12. [12] Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol 2002; 2: 185-194.
13. [13] Baker-LePain JC, Sarzotti M, Fields TA, Li CY, Nicchitta CV. GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. J Exp Med 2002; 196: 1447-1459.
14. [14] Eggleton P, Llewellyn DH. Pathophysiological roles of calreticulin in autoimmune disease. Scand J Immunol 1999; 49: 466-473.
15. [15] Routsias JG, Tzioufas AG. The role of chaperone proteins in autoimmunity. Ann N Y Acad Sci 2006; 1088: 52-64.
16. [16] Rzepecka J, Rausch S, Klotz C, Schnöller C, Kornprobst T, Hagen J, Ignatius R, Lucius R, Hartmann S. Calreticulin from the intestinal nematode Heligmosomoides polygyrus is a Th2-skewing protein and interacts with murine scavenger receptor-A. Mol Immunol 2009; 46: 1109-1119.
17. [17] Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
18. [18] Pulendran B, Banchereau J, Maraskovsky E, Maliszewski C. Modulating the immune response with dendritic cells and their growth factors. Trends Immunol 2001; 22: 41-47.
19. [19] Pinchuk LM, Lee SR, Filipov NM. In vitro atrazine exposure affects the phenotypic and functional maturation of dendritic cells. Toxicol Appl Pharmacol 2007; 223: 206-217.
20. [20] Gaddis DE, Michalek SM, Katz J. Requirement of TLR4 and CD14 in dendritic cell activation by Hemagglutinin B from Porphyromonas gingivalis. Mol Immunol 2009; 46: 2493-2504.
21. [21] Katz S, Ayala V, Santillán G, Boland R. Activation of the PI3K/Akt signaling pathway through P2Y receptors by extracellular ATP is involved in osteoblastic cell proliferation. Arch Biochem Biophys 2011; 513: 144-152.
22. [22] St John EP, Martinson J, Simoes JA, Landay AL, Spear GT. Dendritic cell activation and maturation induced by mucosal fluid from women with bacterial vaginosis. Clin Immunol 2007; 125: 95-102.
23. [23] Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T help er type 1-polarizing program in dendritic cells. Nat Immunol 2005; 6: 769-776.
24. [24] Jähn PS, Zänker KS, Schmitz J, Dzionek A. BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation. Cell Immunol 2010; 265: 15-22.
25. [25] Spiro RG, Zhu Q, Bhoyroo V, Söling HD. Definition of the lectin-like properties of the molecular chaperone, calreticulin, and demonstration of its copurification with endomannosidase from rat liver Golgi. J Biol Chem 1996; 271: 11588-11594.
26. [26] Thomson SP, Williams DB. Delineation of the lectin site of the molecular chaperone calreticulin. Cell Stress Chaperones 2005; 10: 242-251.
27. [27] Wallin RP, Lundqvist A, Moré SH, von Bonin A, Kiessling R, Ljunggren HG. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23: 130-135.
28. [28] Pockley AG. Heat shock proteins as regulators of the immune response. Lancet 2003; 362: 469-476.
29. [29] Martin CA, Kurkowski DL, Valentino AM, Santiago-Schwarz F. Increased intracellular, cell surface, and secreted inducible heat shock protein 70 responses are triggered during the monocyte to dendritic cell (DC) transition by cytokines independently of heat stress and infection and may positively regulate DC growth. J Immunol 2009; 183: 388-399.
30. [30] Cid C, Regidor I, Poveda PD, Alcazar A. Expression of heat shock protein 90 at the cell surface in human neuroblastoma cells. Cell Stress Chaperones 2009; 14: 321-327.
31. [31] Melendez K, Wallen ES, Edwards BS, Mobarak CD, Bear DG, Moseley PL. Heat shock protein 70 and glycoprotein 96 are differentially expressed on the surface of malignant and nonmalignant breast cells. Cell Stress Chaperones 2006; 11: 334-342.
32. [32] Martin CA, Carsons SE, Kowalewski R, Bernstein D, Valentino M, Santiago-Schwarz F. Santiago-Schwarz, Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp) 70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming. J Immunol 2003; 171: 5736-5742.
33. [33] Gross C, Koelch W, DeMaio A, Arispe N, Multhoff G. Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B. J Biol Chem 2003; 278: 41173-41181.
34. [34] Dai J, Liu B, Caudill MM, Zheng H, Qiao Y, Podack ER, Li Z. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immun 2003; 3: 1-7.
35. [35] Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, Mor F, Carmi P, Zanin-Zhorov A, Lider O, Cohen IR. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway. J Immunol 2005; 175: 3594-3602.
36. [36] Flohé SB, Brüggemann J, Lendemans S, Nikulina M, Meierhoff G, Flohé S, Kolb H. Human heat shock protein 6 0 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 2003; 170: 2340-2348.
37. [37] Kol A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells. J Immunol 2000; 164: 13-17.
38. [38] Alyamkina EA, Nikolin VP, Popova NA, Dolgova EV, Proskurina AS, Orishchenko KE, Efremov YR, Chernykh ER, Ostanin AA, Sidorov SV, Ponomarenko DM, Zagrebelniy SN, Bogachev SS, Shurdov MA. A strategy of tumor treatment in mice with doxorubicin-cyclophosphamide combination based on dendritic cell activation by human double-stranded DNA preparation. Genet Vaccines Ther 2010; 8: 7.
39. [39] Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic. Cancer Res 2007; 67: 7941-7944.
40. [40] Goicoechea S, Orr AW, Pallero MA, Eggleton P, Murphy-Ullrich JE. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J Biol Chem 2000; 275: 36358-36368.
41. [41] Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Bio-technol 2007; 25: 192-193.
42. [42] Hiramoto JS, Tsung K, Bedolli M, Norton JA, Hirose R. Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12. J Surg Res 2004; 116: 64-69.
43. [43] Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Müller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Müller GA, Ringert RH. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332-336.
44. [44] Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 2000; 165: 2651-2656.
45. [45] Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191: 1699-1708.
46. [46] Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. Comparison of alpha-Type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine 2008; 26: 2824-2832.
47. [47] de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, Croockewit S, Britten CM, Torensma R, Adema GJ, Figdor CG, Punt CJ. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9: 5091-5100.